Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical impact of rebiopsy among patients with epidermal growth factor receptor-mutant lung adenocarcinoma in a real-world clinical setting.

Thoracic cancer - 1 Mar 2021

Nam Yunha, Kim Ho Cheol, Kim Young-Chul, Jang Seung Hun, Lee Kye Young, Lee Shin Yup, Lee Sang Hoon, Lee Sung Yong, Yoon Seong Hoon, Ryu Jeong-Seon, Jang Tae Won, Chang Yoon Soo, Kim Seung Joon, Park Chan Kwon, Lee Jeong Eun, Jung Chi Young, Choi Chang-Min

Abstract excerpt

BACKGROUND: In this study, we investigated the risk factors of acquired T790M mutation among patients with lung adenocarcinoma with epidermal growth factor receptor (EGFR) tyrosine mutation who were treated with EGFR-tyrosine kinase inhibitors (TKIs). The aim was to identify the clinical impact of rebiopsy. METHODS: This multicenter, retrospective cohort study was conducted in South Korea from January 2007 to...

Topics

Join the communities discussing this publication.

Adenocarcinoma of Lung
Aged
Biopsy
ErbB Receptors
Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 33529490
DOI: 10.1111/1759-7714.13857
PMCID: PMC7952806

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical impact of rebiopsy among patients with epidermal growth factor receptor-mutant lung adenocarcinoma in a real-world clinical setting.PMID 33529490Read ↗

T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas Harboring EGFR Mutations.Semantic proximity Read ↗

Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.Semantic proximity Read ↗

Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib.Semantic proximity Read ↗

First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study.Semantic proximity Read ↗

Should We Perform Repeated Re-biopsy for the Detection of T790M Mutation?Semantic proximity Read ↗

Real-world data on efficacy and safety of osimertinib in non-small cell lung cancer patients with EGFR T790M mutation detected by first and repeat rebiopsy.Semantic proximity Read ↗

Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure.Semantic proximity Read ↗

The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M.Semantic proximity Read ↗

Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI.Semantic proximity Read ↗

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC.Semantic proximity Read ↗

Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.